SBRT and Hypofractionation in Prostate Cancer

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.

The company plans to initiate the phase 2 monotherapy trial by mid-year.